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ScienceDirectAldolases are seen as an attractive route to the production of
biologically important compounds due to their ability to form
carbon–carbon bonds. However, for many industrial reactions
there are no naturally occurring enzymes, and so many different
engineering approaches have been used to address this
problem. Engineering methods have been used to alter the
stability, substrate specificity and stereospecificity of aldolases
to produce excellent enzymes for biocatalytic processes.
Recently greater understanding of the aldolase mechanism has
allowed many successes with both rational engineering
approaches and computational design of aldolases. Rational
engineering approaches have produced desired enzymes
quickly and efficiently while combination of computational
design with laboratory methods has created enzymes with
activity approaching that of natural enzymes.
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Introduction
The formation of carbon-carbon bonds is central to
organic chemistry and the aldol condensation [1–4], the
reaction of two carbonyl compounds to generate a new b-
hydroxyl carbonyl compound, is an important tool in
building up complexity of organic molecules, since up
to two new stereogenic centres are made during the
formation of the new C–C bond. Aldol structural units
are found in many naturally occurring molecules and are
the result of reactions catalysed by the aldolase family of
enzymes. These enzymes convert their substrates into§ This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original
author and source are credited.
www.sciencedirect.com the aldol products in high yield with high specificity
under mild conditions, but also with great control over
the relative and absolute configurations of the new stereo-
genic centres created. These properties make aldolase-
catalysed routes attractive for the production of biologi-
cally significant compounds, as these tend to contain
multiple functional groups and are often water-soluble
making conventional synthetic routes more difficult [5].
However, naturally occurring aldolases do not exist for
many industrially important reactions and protein engin-
eering, directed evolution and de novo enzyme design [6–
10] have all been used to alter properties such as stability,
substrate specificity and stereoselectivity to produce tai-
lor made aldolases for use as biocatalysts. Since we
reviewed this area in 2008 [11] it is pleasing to see an
increasing use of protein engineering to manipulate aldo-
lases as new biocatalysts, both in their own right and as
part of chemical cascade reactions leading to important
products (see Table 1 for a summary of recent examples
of engineering aldolases). Additionally, the growing area
of computational enzyme design [12] has shown the way
towards de novo designed aldolases [13], especially when
combined with directed evolution to improve the activity
of the ‘designer’ aldolases [14].
Engineering of aldolases for enhanced
stability and activity
Enzymes have many desirable features as biocatalysts,
but denaturation at higher temperatures, intolerance
towards organic solvents and the possibility of substrate
inhibition are drawbacks which may limit their use in
industrial environments or enzymatic cascade reactions.
However, these problems may be overcome by engin-
eering. For example, the thermostability and solvent
tolerance of fructose-1,6-bisphosphate aldolase (FBP-
aldolase) was increased using family DNA shuffling
[15] of the fda genes from Escherichia coli and Edwardsiella
ictaluri and a fourth generation variant was identified
which displayed an average 280-fold higher half-life at
53 8C than either parent. The same variant also displayed
enhanced activity in various polar and non-polar organic
solvents — directed evolution in this case providing
beneficial properties over and above those that were
screened for.
Aldolases have also been engineered towards enhanced
activity at lower temperature as this may be more
beneficial in an industrial setting. A random library,
generated by error-prone PCR, of the hyperthermophilic
2-keto-3-deoxygluconate aldolase (KDG-aldolase) from
Sulfolobus acidocaldarius which has an optimal activity for
the condensation of D,L-glyceraldehyde with pyruvate atCurrent Opinion in Chemical Biology 2014, 19:25–33
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Table 1
A selection of recent examples of engineering of aldolases for use as biocatalysts
Enzyme Reactions Ref.
2-Deoxyribose-5-
phosphate aldolase
Natural [19]
Engineered
.............................................................................................................................................................................................................
2-Keto-3-deoxy-6-
phosphogluconate
aldolase
Natural [20,21]
Engineered
.............................................................................................................................................................................................................
Rhamnulose-1-
phosphate
aldolase
Natural [26]
Engineered
.............................................................................................................................................................................................................
Fructose-6-
phosphate
aldolase
Natural [29,30]
Engineered
.............................................................................................................................................................................................................
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Table 1 (Continued )
Enzyme Reactions Ref.
Transaldolase Natural [31,32]
Engineered
.............................................................................................................................................................................................................
4-Oxocrotonate
tautomerase
Natural [34]
Engineered
.............................................................................................................................................................................................................
BphI Natural [42,47]
Engineered
.............................................................................................................................................................................................................
2-Keto-3-deoxygluconate
aldolase
Natural [43]
Engineered [43]
Engineered increased stability at lower temperatures
www.sciencedirect.com Current Opinion in Chemical Biology 2014, 19:25–33
28 Biocatalysis and biotransformation95 8C, was screened for enhanced activity at 50 8C. The
V193A variant has threefold higher activity than the wild-
type enzyme, with the highest increase in activity at 40 8C
for both the natural aldehyde acceptor, as well as a
number of unnatural acceptor aldehydes. Interestingly,
this mutation had little influence on the thermostability
of the enzyme as the observed t1/2 at 90 8C was similar to
that of the parent aldolase [16]. This decoupling of
activity and stability demonstrates the potential for opti-
mizing extremely thermostable aldolases for synthesis
reactions at moderate temperatures.
The engineering of aldolases towards enhanced activity at
different temperatures may help to make them applicable
for use in cascade reactions, where combinations of ther-
mophilic and mesophilic enzymes may require their
optimal temperatures to be matched. In addition,
increased activity may also be needed to generate useful
enzymes for cascade reactions. For example the rate-
limiting enzyme in the bioconversion of xylose to ethanol
in Pichia stipites is a transaldolase and directed evolution
was used to create a transaldolase with increased activity
in converting sedoheptulose 7-phosphate (S7P) and gly-
ceraldehyde 3-phosphate (G3P) into fructose 6-phos-
phate (F6P) and erythrose 4-phosphate (E4P) and
therefore increase the production of ethanol, a conversion
that is of great interest to industry as it may lead to
renewable fuels [17]. An error prone PCR strategy was
used and two variants were identified, Q263R and
K190 M, with >5-fold increases in kcat/KM in vitro. The
Q263R mutant was introduced into P. stipitis using hom-
ologous recombination and ethanol production in the
resulting strain was shown to be 36% higher than with
the parental strain [18].
Another example of the beneficial engineering of an
aldolase for use in cascade reactions involves 2-deoxy-
ribose-5-phosphate aldolase (DERA). This enzyme has
been applied as a biocatalyst for the synthesis of (3R,5S)-
6-chloro-2,4,6-trideoxyhexapyranoside, a valuable chiral
precursor for statin drugs such as atorvastatin (Lipitor).
(3R,5S)-6-chloro-2,4,6-trideoxyhexapyranoside can be
formed from chloroacetaldehyde (CAA) and two equiva-
lents of acetaldehyde in a sequential tandem enzymic
aldol reaction (Table 1); however, economically efficient
large-scale synthesis was hampered by the enzyme’s low
affinity for CAA and the concentrations of CAA needed
for efficient biocatalysis lead to rapid and permanent
enzyme inactivation. Error prone PCR and DNA recom-
bination were used to engineer DERA for increased
stability to CAA, and a number of variants resistant to
inhibition at CAA concentrations up to 400 mM CAA
were identified (e.g. variant M185V or variants altered
at the C-terminus). In addition, variants with increased
activity were also identified by error-prone PCR, for
example variant F200I, which showed 14-fold improved
activity and a twofold to threefold lower KM for CAA.Current Opinion in Chemical Biology 2014, 19:25–33 Subsequent combination of the F200I mutation with the
DY259 C-terminal deletion or with a variant containing
Y259T and a 9-residue extension to the C-terminus
resulted in 10-fold higher catalytic activity in the pre-
sence of 1 M acetaldehyde and 500 mM CAA than the
wild-type under industrially relevant conditions [19].
Engineering aldolases with varied substrate
specificities
Enzymes have high specificity, but the narrow substrate
range is problematic if no natural enzyme exists for a
desired, specific reaction. There are many examples
where protein engineering has been applied to aldolases
to broaden or change the substrate specificities, for both
the aldehyde acceptor and the ketone donor, and to
exploit catalytic promiscuity for the production of syn-
thetically useful compounds.
The Class I pyruvate-dependent 2-keto-3-deoxy-6-phos-
phogluconate-aldolase (KDPGA) catalyses the cleavage
of 2-keto-3-deoxy-6-phosphogluconate (KDPG) into pyr-
uvate and glyceraldehyde 3-phosphate and has been the
subject of many studies to alter its substrate specificity
[20,21–24]. Recent engineering has used both directed
evolution [21] and structure-based mutagenesis [20] to
expand its substrate range to non-functionalized electro-
philic substrates and pyridine carboxaldehyde substrates,
respectively. Furthermore, the activity of the variant
KDPGA with the pyridine carboxaldehyde substrate
(4S)-2-keto-4-hydroxy-4-(20-pyridyl) butyrate (S-KHPB)
maintains high stereoselectivity at a similar rate to that of
the wild-type enzyme with KDPG. These new substrate
specificities could prove useful in the synthesis of import-
ant antifungal and antimicrobial compounds.
In general, aldolases are much more specific for their aldol
donor substrate than for their acceptor. This has proved
problematic, especially with the dihydroxyacetone phos-
phate (DHAP) dependant aldolases, where DHAP is
expensive, relatively unstable and where the phosphate
group is often not required in the final product. There
have been a number of attempts to redesign these
enzymes to use the non-phosphorylated donor, dihydrox-
yacetone (DHA), by using directed evolution [25] or
rational methods using point mutations to redesign the
phosphate binding pocket [26]. In this respect fructose-
6-phosphate aldolase (FSA) is of great interest as it has
been shown to utilize multiple donor substrates such as
dihydroxyacetone (DHA), hydroxyacetone and hydroxy-
butanone [27]. FSA also provides a route to the pro-
duction of iminocyclitols which are attractive drug
candidates [28]. FSA has been the subject of many studies
to alter its substrate specificity for different acceptor
aldehydes and to increase its affinity for the specific donor
DHA [29,30]. Another enzyme that uses DHA rather
than DHAP is transaldolase (Tal) and, interestingly,
FSA activity has been conferred on this enzyme bywww.sciencedirect.com
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(F178Y) in the active site [31]. This F178Y variant has
also been the subject of further study to increase its
activity with non-phosphorylated acceptor aldehydes.
Structure-guided mutagenesis identified residues in the
phosphate binding pocket that, when mutated, prevent
phosphorylated acceptors from binding. This has pro-
duced an enzyme that can synthesize polyhydroxylated,
non-phosphorylated compounds and be used in enzy-
matic cascade synthesis of this type of compound [32].
Many enzymes have been shown to have catalytic prom-
iscuity and as well as using engineering to subvert the
substrate specificity of natural aldolases, attempts are now
being made to enhance the catalytic promiscuity of other
enzyme classes to produce novel aldolases. An early
example of the conversion of one enzyme activity into
another type of reaction was the conversion of an alanine
racemase into an aldolase by a single active site point
mutation [33]. This variant enzyme catalysed a reaction
similar to threonine aldolase with rates and specificities
comparable with the native enzyme. More recently 4-
oxalocrotonate tautomerase (4-OT) was shown to be
promiscuous in having low aldolase activity towards the
condensation of acetaldehyde and benzaldehyde to yield
cinnamaldehyde. This low activity has been enhanced by
a single point mutation, F50A, which increased the kcat/
KM for the aldolase activity by 600-fold compared to that
of the wild-type [34].
Lipases have also been reported to display promiscuous
aldolase activity [35,36] and recently asymmetric aldol
reactions between acetone and 4-nitrobenzaldehyde (cat-
alysed by porcine pancreas lipase) [37] and aromatic and
heteroaromatic aldehydes with cyclic ketones (catalysed
by chymopapain, nuclease p1, alkaline protease BLAP
and acidic protease AUAP) [38,39] have been described.
Care must, however, be taken since some of these appar-
ent promiscuous activities have been shown to be due to a
combination of the natural activity of the enzyme coupled
with spontaneous chemical reaction with the other aldol
partner to generate the misleading promiscuous activity
(reviewed in [40]). Promiscuous aldolase activity has also
been found for macrophomate synthase which catalyses
the addition of the enolate of pyruvate (generated on the
enzyme by decarboxylation of oxaloacetate) with a wide
range of structurally complex aldehydes to yield 3-deox-
ysugars [41]. This system has advantages over known
natural pyruvate-dependent aldolases as it has a broad
substrate spectrum.
Engineering of aldolases for increased
stereospecificity
The biological outcomes of the interactions of stereoi-
somers of small drug molecules with their targets can be
dramatically different and the global market for enantio-
merically pure, active pharmaceutical ingredients (APIs)www.sciencedirect.com is increasing rapidly. However, the chemical synthesis of
enantiomerically pure compounds can be challenging,
and most often relies on the classical resolution of a
racemate. Harnessing enzymes as chiral catalysts is viable
in both the small scale and industrial synthesis of enan-
tiomerically enriched compounds. In this respect, protein
engineering of enzymes to enhance or alter the stereo-
chemical outcome of an enzyme reaction is of great
importance and much attention has been focused on
aldolases, as up to two stereo-centres may be generated
during the carbon-carbon bond forming step [11]. In
recent years there has been much progress in using many
engineering methods ranging from directed evolution
[42] to rational redesign [43,44,45] to produce products
with high stereochemical control. Improved biocatalysts
have also been found by screening available environmen-
tal DNA libraries. In this way, a natural variant of DERA
was discovered that produced (3R,5S)-6-chloro-2,4,6-tri-
deoxyhexapyranoside (see above), with a diastereomeric
excess of 99.8% and an enantiomeric excess of 99.9% [46].
This variant also had a higher tolerance to the inhibiting
substrate chloroacetaldehyde and was more efficient than
the E. coli variant, allowing lower quantities of the
enzyme to be used in the process. Both these factors
increase the commercial and industrial viability of the
biocatalytic process.
The ability to engineer or evolve the stereochemical
outcome of an aldolase reaction was first demonstrated
for tagatose-1,6-bisphosphate aldolase [47] and N-acetyl-
neuraminic acid lyase [42]. More recently, rational rede-
sign has been carried out on the Class II aldolase BphI to
switch the stereochemical outcome of the reaction of
pyruvate with acetaldehyde. First, the substrate speci-
ficity of BphI was changed to favour propionaldehyde
over acetaldehyde [48] using site-directed mutagenesis
based on modelling of the structure using the orthologous
enzyme DmpG [49]. While wild-type BphI is highly
selective for si face attack of the pyruvate enolate onto
the aldehyde carbonyl to produce 4(S)-hydroxy-2-oxo-
pentanoate as product, two variants (Y290F and Y290S)
utilize both the 4(S)-enantiomer and the 4(R)-enantiomer
[48]. It is suggested that the hydroxyl group of Tyr290
sterically restricts the binding of the 4(R) enantiomer and
its removal permits both isomers to bind. Further model-
ling suggested that Leu87 interacts with the C4-methyl of
4(S)-hydroxy-2-oxoacids. Double mutants at positions 87
and 290 were constructed and the stereochemical out-
come of the reaction was found to be switched from 4S in
the wild-type to 4R in the L87N/Y290F and L87W/Y290F
double mutants [43].
Another example of engineering of stereochemistry
involves the enzyme 2-keto-3-deoxygluconate aldolase
(KDGA). This enzyme has broad substrate specificity but
poor diastereo-control for the reaction of pyruvate, either
with the natural substrate D-glyceraldehyde (where aCurrent Opinion in Chemical Biology 2014, 19:25–33
30 Biocatalysis and biotransformation55:45 mixture of D-2-keto-3-deoxy-gluconate (D-KDGlu):
D-2-keto-3-deoxy-galactonate (D-KDGal) is produced) or
with the enantiomer of the substrate, L-glyceraldehyde.
However stereoselectivity could be engineered into this
reaction by conformationally locking the substrate as
either the D-glyceraldehyde acetonide or the (S)-enantio-
mer [50]. To achieve the same goal by engineering the
enzyme, detailed X-ray crystallographic analysis of the
structures of both D-KDGlu and D-KDGal bound to
KDGA was used [51] to identify residues for mutation
to generate a pair of complementary stereoselective
enzymes [44]. Interest was focused on the differences
in binding the C5 and C6 hydroxyl groups of D-KDGlu
and D-KDGal and the epimeric C4-OH group of bothFigure 1
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The top panel shows the attack of the lysine bound enamine form of pyruvat
KDGlu or KDGal. The bottom panel shows the binding interactions of KDGlu (
in the stabilization of C5-OH and C6-OH of KDGlu and KDGal can be seen. T
Tyr-132 whereas the C5-OH residue of D-KDGlu makes water mediated hydro
in the bonding of the terminal C6-OH residue; in D-KDGal it interacts directl
bonding with Tyr-132 and water mediated hydrogen bonding.
Current Opinion in Chemical Biology 2014, 19:25–33 diastereoisomers and lead to saturation mutagenesis of
Thr-157 (Figure 1) and combination with mutations at
Tyr132. Two double mutants, T157C/Y132V and T157F/
Y132V, were found which catalysed the stereoselective
formation of KDGlu in an improved 92%dr. To create
the complementary KDGal-specific enzyme, a double
mutant T157V/A198L was identified from structural
information that would disrupt the hydrogen bonding
network for KDGlu and this enzyme resulted in the
production of KDGal with an improved 72%dr. Study
of the enzyme structure suggested that the binding of
KDGal could be further improved by adding a third
mutation (at Asp-181) to create the T157V/A198L/
D181Q triple mutant, which indeed showed that the drSER-241
ASN-245
ALA-198
THR-44
KDGal
OHO
-OOC OH
OH
OH
OH
(Re )
TYR-130
LYS-155
TYR-132
THR-157
Current Opinion in Chemical Biology
e onto the either the Si or Re face of D-glyceraldehyde, to produce either
on the left) and KDGal (on the right) in the active site of KDGA. Differences
he C5-OH residue of D-KDGal was shown to hydrogen bond directly with
gen-bonding interactions within the active site. There are also differences
y with Thr-44 whereas in D-KDGlu it is directly stabilized by hydrogen
www.sciencedirect.com
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Figure 2
(a) (b) (c)
Current Opinion in Chemical Biology
The remodelling of the active site of the designer retroaldolase RA95.0 [14]. (a) The structure of RA95.0 (PDB code 4A29) showing the designed
catalytic lysine residue, Lys210 (yellow) and the 1, 3 diketone mechanism-based inhibitor (green). (b) The structure of variant RA95.5 (PDB code 4A2S)
showing the two different binding modes of inhibitor, one using Lys210 (yellow) and the other, the newly introduced Lys83 (orange). (c) The structure of
RA95.5-5 (PDB code 4A2R) showing that the active site location has switched during evolution to the new lysine Lys83, and that Lys210 is not modified
in RA95.5-5.for the formation of KDGal could be improved to 88%dr.
This work [44] demonstrated again that stereochemically
complementary variants can be produced from a stereo-
chemically promiscuous enzyme, but also highlighted the
power of structurally informed mutagenesis in the con-
struction of new aldolases as biocatalysts.
Computational design of aldolases
Much progress has been made towards altering existing
enzymes for tailored, stereochemically controlled aldol
condensations using a combination of protein engineer-
ing strategies. An increasingly common feature of such
experiments is the combination of engineering and/or
directed evolution with structural modelling, and com-
putational strategies [7,12]. An ultimate example is the
de novo computational design of an aldolase [13].
Although the starting activities of such designed
enzymes is low, random mutagenesis at the active site
and at more distant locations can be used to improve the
activity [52]. To explore the structural basis of these
changes and to augment the activity of the designer
aldolase, further rounds of directed evolution were car-
ried out and X-ray crystal structures of the enzyme in
complex with a mechanism-based inhibitor were solved
after each stage of evolution. In the initial designer
enzyme (RA95.0) the inhibitor reacts covalently with
Lys210 as was intended for the designer enzyme. How-
ever, during the evolution of increased activity (variant
RA95.5) a new lysine was introduced into the active site
(Lys83) during cassette mutagenesis and unexpectedly
RA95.5 is modified twice by the mechanism-based
inhibitor — once at Lys210, as in RA95.0, and once at
the newly introduced Lys83 (Figure 2). After further
rounds of error prone PCR variant RA95.5-5 waswww.sciencedirect.com constructed which contained additional mutations and
which was >20-fold more efficient than RA95.5 and
>1700-fold more active than the original in silico design.
Structurally this variant showed further modulation of
loops of the protein, but interestingly was only modified
by the inhibitor at Lys83, implying that this new binding
site is more evolvable than the original designer site.
Subjecting this evolved retro-aldolase to further error
prone PCR produced an enzyme with activity approach-
ing that of a natural aldolase, notable for an artificial
enzyme. This work demonstrates how powerful the
combination of computational and traditional methods
can be and also allows insight into the mechanisms that
lead to enhanced catalytic efficiency [52].
Conclusions and future perspectives
The synthetic utility of aldolase enzymes may be
substantially increased using protein engineering
approaches. Complementary approaches have been
exploited to improve the properties of aldolases including
their stability, substrate scope and stereoselectivity.
Excitingly, the increased understanding of the function
of aldolase variants, together with computational
approaches, can help focus protein engineering exper-
iments on specific, functionally important residues. Such
approaches can improve the efficiency of searching within
sequence space, enabling more rapid discovery of
enzymes with the required synthetically valuable proper-
ties. The future use of these important enzymes looks
bright with the ability to link engineered aldolases with
other enzymes in novel constructed pathways and organ-
isms opening the way to their increased use in synthetic
biology to more easily produce valuable but useful com-
plex compounds.Current Opinion in Chemical Biology 2014, 19:25–33
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